<DOC>
	<DOCNO>NCT02914769</DOCNO>
	<brief_summary>The purpose present trial test efficacy Ayahuasca treatment-resistant depression . Ayahuasca decoction two plant , long used Amazonian Amerindians . Traditionally , prepared decoction bush ( Psychotria viridis ) liana ( Banisteriopsis caapi ) . P. viridis rich source N , N-dimethyltryptamine ( DMT ) , serotonergic agonist , B. caapi contain potent monoamine oxidase-A inhibitor ( MAOi-A ) , harmine , harmaline . The study design randomize placebo control trial two parallel arm , also evaluate change different biomarkers depression include anatomical functional Magnetic Resonance Imaging ( MRI ) , serum level BDNF , TNF-a , cortisol , IL-6 , IL-10 , polysomnography , neuropsychological , psychiatric scale questionnaire .</brief_summary>
	<brief_title>Antidepressant Effects Ayahuasca : Randomized Placebo Controlled Trial Treatment Resistant Depression</brief_title>
	<detailed_description>1 ) Background The therapeutic effectiveness currently available antidepressant low . Less 50 % patient achieve remission single treatment , 30 % four different treatment . Besides low response rate , pharmacological treatment associate several side effect response onset usually long ( ~2-3 week ) . Thus , great effort make development alternative antidepressant . For instance , ketamine , N-methyl-D-aspartate ( NMDA ) receptor antagonist , rapid potent antidepressant effect treatment major depressive bipolar disorder . This proposal aim test antidepressant effect Ayahuasca , traditionally prepared decoction two plant : Psychotria viridis Banisteriopsis caapi , long used Amazonian Amerindians . P. viridis rich source serotonergic agonist N , N-dimethyltryptamine ( DMT ) , whereas B. caapi contain potent monoamine oxidase-A inhibitor ( MAOi-A ) harmine , harmaline , tetrahydroharmine , serotonin reuptake inhibitor . Common effect Ayahuasca include sedation , gastrointestinal distress , change spatiotemporal scaling , dissociation , sense well-being , insight , feeling apprehension , increase interoceptive attention sensory pseudo-hallucinations . Effects begin 30-40 min oral intake , last 4 hour . Previous study suggest absence psychological , neuropsychological psychiatric harm cause prolonged Ayahuasca consumption , addictive , contrary , also show promise treat addiction . Recently , two preliminary open label study test tolerability , safety antidepressant effect Ayahuasca treatment-resistant depression . In first study , six patient recruit , second , 17 patient . The result show significant decrease depression severity ( HAM-D &amp; MADRS scale ) already 2 hour intake , last 21 day . Although result promise , must consider caution , specially due lack control placebo effect , generally high clinical trial . Thus , present study randomize placebo-controlled trial 50 patient treatment resistant depression . Besides Antidepressant effect Ayahuasca , study also evaluate different biomarkers depression , include anatomical functional Magnetic Resonance Imaging ( MRI ) , serum level BDNF , TNF-a , cortisol , IL-6 , IL-10 , polysomnography , neuropsychological psychiatric scale questionnaire . 2 . Methods All 50 patient undergo routine evaluation , include complete blood test individual glycemic profile , serum cholesterol triglyceride , plasma sodium potassium , urea creatinine . Patients undergo wash-out period , 7 14 day prior experimental session , depend lifetime antidepressant use . Experiments take place Hospital Universit√°rio Onofre Lopes , tertiary university hospital affiliate Universidade Federal Rio Grande Norte ( UFRN ) , Brazil . In treatment session , 25 patient drink Ayahuasca , 25 drink inert placebo . Psychiatric scale ( HAM-D , MADRS , BPRS , CADSS YMRS ) complete treatment session , day one ( -D1 ) , one day ( +D1 ) , two day ( +D2 ) , seven day ( +D7 ) , fourteen day ( +D14 ) , one month ( +M1 ) , six month ( +M6 ) follow treatment session . The following exam also conduct D-1 D+1 : neuropsychological test ( watch test , trail test , N-back ) , structural functional MRI , polysomnography blood testing ( BDNF , TNF-a , cortisol , oxytocin , IL-6 , IL-10 ) .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Depressive Disorder , Treatment-Resistant</mesh_term>
	<mesh_term>Antidepressive Agents</mesh_term>
	<criteria>Age : 1860 year old ; Diagnostic major depressive disorder ( DSMIV ) ; At least two previous unsuccessful antidepressant medication ; Current depressive episode ( HAMD &gt; = 17 ) . History psychosis ; Present past history bipolar disorder schizophrenia ; Diagnosis current clinical disease , base history , physical examination routine hematologic biochemical test ; Serious imminent suicidal risk ; Pregnancy , current drug alcohol dependence ; Previous experience ayahuasca .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Depression</keyword>
	<keyword>Ayahuasca</keyword>
	<keyword>Psychedelics</keyword>
</DOC>